One page, thousands of outlets. See who else covered it.
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
We haven't written up this one. The Age has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
(MedPage Today) -- Use of active surveillance for low- and favorable intermediate-risk prostate cancer more than tripled since 2005, according to a large study of veterans.
Outdated state laws are threatening Nigeria’s disease outbreak preparedness, warns NCDC. Learn how weak public health laws undermine national response effo Read More…
Nairobi: The Ebola outbreak in Congo is “far from being under control,” World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus said at an emergency meeting on Tuesday. T...
To what extent does the allocation of aid for combating disease correspond to disease burden? LMU researchers have developed a machine-learning pipeline that helps uncover relative discrepancies in…
The company said a critical late-stage study of an experimental vaccine showed the treatment stopped melanoma from spreading.
